doi:10.3969/j.issn.1004-583X.2024.07.014

Abstract

CLC Number:

R575.2

Add to citation manager EndNote|Ris|BibTeX

URL: https://lchc.magtechjournal.com/EN/10.3969/j.issn.1004-583X.2024.07.014

https://lchc.magtechjournal.com/EN/Y2024/V39/I7/658

Figures/Tables 2

References 55

[1]	Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis[J]. J Hepatol, 2017, 67(5): 950-956. doi: S0168-8278(17)32145-1 pmid: 28716745
[2]	Koupenova M, Kehrel BE, Corkrey HA, et al. Thrombosis and platelets: An update[J]. Eur Heart J, 2017, 38(11): 785-791. doi: 10.1093/eurheartj/ehw550 pmid: 28039338
[3]	张译之, 陈煜. 肝硬化患者的止血平衡改变[J]. 肝脏, 2020, 25(8): 786-788. doi: 10.1159/000339151 pmid: 22796658
[4]	Hugenholtz GCG, Lisman T, Stravitz RT. Thromboelastography does not predict outcome in different etiologies of cirrhosis[J]. Res Pract Thromb Haemost, 2017, 1(2): 275-285. doi: 10.1002/rth2.12037 pmid: 30046697
[5]	Fisher C, Patel VC, Stoy SH, et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure[J]. J Crit Care, 2018, 43: 54-60. doi: S0883-9441(17)30275-7 pmid: 28843665
[6]	丁靖诺, 赵卫峰. 肝硬化状态对血小板数目及功能变化的影响分析[J]. 胃肠病学和肝病学杂志, 2022, 31(7):725-730.
[7]	Naohisa W, Haruki U, Takashi S, et al. Impact of anti-GPIIb/IIIa antibody-producing B cells as a predictor of the response to lusutrombopag in thrombocytopenic patients with liver disease[J]. Digestive diseases, 2021, 39(3):234-242.
[8]	Lisman T, Arefaine B, Adelmeijer J, et al. Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease[J]. J Thromb Haemost, 2021, 19(1): 85-95.
[9]	Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis[J]. Gastroenterology, 2009, 137(6): 2105-2111. doi: 10.1053/j.gastro.2009.08.045 pmid: 19706293
[10]	Lisman T, Bos S, Intagliata NM. Mechanisms of enhanced thrombin-generating capacity in patients with cirrhosis[J]. J Thromb Haemost, 2018, 16(6): 1128-1131. doi: 10.1111/jth.14020 pmid: 29633495
[11]	El Bokl MA, Shawky A, Riad GS, et al. Procoagulant versus anticoagulant factors in cirrhotic patients[J]. Arab J Gastroenterol, 2014, 15(3-4): 123-129. doi: 10.1016/j.ajg.2014.08.003 pmid: 25249231
[12]	Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method[J]. Hepatology, 2010, 52(1): 249-255. doi: 10.1002/hep.23653 pmid: 20578143
[13]	Wilhelm AR, Parsons NA, Samelson-Jones BJ, et al. Activated protein C has a regulatory role in factor VIII function[J]. Blood, 2021, 137(18):2532-2543.
[14]	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis[J]. J Hepatol, 2022, 76(5): 1151-1184. doi: 10.1016/j.jhep.2021.09.003 pmid: 35300861
[15]	Francis JL, Armstrong DJ. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease[J]. Haemostasis, 1982, 11(4): 215-222. doi: 10.1159/000214666 pmid: 6290353
[16]	Hugenholtz GC, Macrae F, Adelmeijer J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen[J]. J Thromb Haemost, 2016, 14(5): 1054-1066. doi: 10.1111/jth.13278 pmid: 26833718
[17]	Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis[J]. Hepatology, 2003, 38(1): 230-237. pmid: 12830006
[18]	Rijken DC, Kock EL, Guimarães AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests[J]. J Thromb Haemost, 2012, 10(10): 2116-2122. doi: 10.1111/j.1538-7836.2012.04901.x pmid: 22906184
[19]	Leebeek FW, Kluft C, Knot EA, et al. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis[J]. Gastroenterology, 1991, 101(5): 1382-1390. doi: 10.1016/0016-5085(91)90092-y pmid: 1718809
[20]	Hersch SL, Kunelis T, Francis RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibitor[J]. Blood, 1987, 69(5): 1315-1319. pmid: 2436684
[21]	Labidi A, Baccouche H, Fekih M, et al. The relationship between coagulation disorders and the risk of bleeding in cirrhotic patients[J]. Ann Hepatol, 2019, 18(4): 627-632. doi: S1665-2681(19)30071-7 pmid: 31097395
[22]	Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 73(1): 366-413. doi: 10.1002/hep.31646 pmid: 33219529
[23]	黄志寅, 高锦航. 保护门静脉——从病理生理到临床处理决策[J]. 临床肝胆病杂志, 2021, 37(12): 2760-2763.
[24]	Muciño-Bermejo J, Carrillo-Esper R, Uribe M, et al. Coagulation abnormalities in the cirrhotic patient[J]. Ann hepatol, 2013, 12(5): 713-724. pmid: 24018489
[25]	Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease[J]. Clin Gastroenterol H, 2010, 8(10): 899-902; quiz e109. doi: 10.1016/j.cgh.2010.06.018 pmid: 20601131
[26]	唐承薇. 慢性肝病与血小板减少:临床处理观念的转变[J]. 实用肝脏病杂志, 2019, 22(4): 457-458.
[27]	Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy[J]. Brit J Anaesth, 2010, 105(2): 116-121.
[28]	Giannini EG, Giambruno E, Brunacci M, et al. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients[J]. Ann Hepatol, 2018, 17(5): 830-835. doi: 10.5604/01.3001.0012.0775 pmid: 30145561
[29]	Drolz A, Horvatits T, Roedl K, et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis[J]. Hepatology, 2016, 64(2): 556-568. doi: 10.1002/hep.28628 pmid: 27124745
[30]	Budnick IM, Davis JPE, Sundararaghavan A, et al. Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically Ill cirrhosis patients[J]. Thromb Haemostasis, 2021, 121(10): 1317-1325. doi: 10.1055/a-1355-3716 pmid: 33450778
[31]	Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis[J]. J Hepatol, 2022, 76(6): 1291-1305. doi: 10.1016/j.jhep.2021.11.004 pmid: 35589251
[32]	祁兴顺, 杨玲. 肝硬化门静脉血栓管理专家共识(2020年,上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674.
[33]	Jepsen P, Tapper EB, Deleuran T, et al. Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: A danish nation-wide cohort study[J]. Hepatology, 2021, 74(5): 2725-2734. doi: 10.1002/hep.32019 pmid: 34137045
[34]	Violi F, Ferro D. Clotting activation and hyperfibrinolysis in cirrhosis: Implication for bleeding and thrombosis[J]. Semin Thromb Hemost, 2013, 39(4): 426-433. doi: 10.1055/s-0033-1334144 pmid: 23487343
[35]	Semeraro N, Biondi A, Lorenzet R, et al. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites[J]. Immunology, 1983, 50(4): 529-535. pmid: 6654386
[36]	Moore KL, Andreoli SP, Esmon NL, et al. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro[J]. J Clin Invest, 1987, 79(1): 124-130. doi: 10.1172/JCI112772 pmid: 3025256
[37]	Lin HC, Yang YY, Tsai TH, et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension[J]. J Hepatol, 2011, 54(6): 1145-1153.
[38]	Schierwagen R, Alvarez-Silva C, Madsen MSA, et al. Circulating microbiome in blood of different circulatory compartments[J]. Gut, 2019, 68(3): 578-580. doi: 10.1136/gutjnl-2018-316227 pmid: 29581241
[39]	Violi F, Ferro D, Basili S, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients[J]. Thromb haemostasis, 1997, 77(1): 44-47. pmid: 9031447
[40]	Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors[J]. J Hepatol, 2021, 75(6): 1367-1376. doi: 10.1016/j.jhep.2021.07.020 pmid: 34333101
[41]	He Y, Yuan S, Guo X, et al. Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis[J]. BMC Gastroenterol, 2021, 21(1): 253. doi: 10.1186/s12876-021-01832-3 pmid: 34098892
[42]	Driever EG, Von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus[J]. Hepatology, 2022, 75(4): 898-911.
[43]	Anwar MA, Shalhoub J, Lim CS, et al. The effect of pressure-induced mechanical stretch on vascular wall differential gene expression[J]. J Vasc Res, 2012, 49(6): 463-478.
[44]	Ahanchi SS, Tsihlis ND, Kibbe MR. The role of nitric oxide in the pathophysiology of intimal hyperplasia[J]. J Vasc Surg, 2007, 45 (Suppl A): A64-73.
[45]	Sigel B, Swami V, Can A, et al. Intimal hyperplasia producing thrombus organization in an experimental venous thrombosis model[J]. J Vasc Surg, 1994, 19(2): 350-360. pmid: 8114194
[46]	肖春桃, 李贤秋, 甘佩灵, 等. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响[J]. 临床肝胆病杂志, 2021, 37(8):1829-1835.
[47]	何青莲, 余保平, 肖勇. 肝硬化食管胃静脉曲张出血患者内镜治疗后再出血的危险因素分析[J]. 肝脏, 2023, 28(1):55-60.
[48]	Wang L, Guo X, Bai Z, et al. Impact of asymptomatic superior mesenteric vein thrombosis on the outcomes of patients with liver cirrhosis[J]. Thromb Haemostasis, 2022, 122(12): 2019-2029.
[49]	Rugivarodom M, Charatcharoenwitthaya P. Nontumoral portal vein thrombosis: A challenging consequence of liver cirrhosis[J]. J Clin Transl Hepato, 2020, 8(4): 432-444.
[50]	Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: Results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667.
[51]	Noronha Ferreira C, Marinho RT, Cortez-Pinto H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study[J]. Liver int, 2019, 39(8): 1459-1467. doi: 10.1111/liv.14121 pmid: 31021512
[52]	De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis[J]. Liver int, 2017, 37(5): 694-699. doi: 10.1111/liv.13285 pmid: 27778440
[53]	Hum J, Shatzel JJ, Jou JH, et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis[J]. Eur J Haematol, 2017, 98(4): 393-397. doi: 10.1111/ejh.12844 pmid: 28009449
[54]	Mort JF, Davis JPE, Mahoro G, et al. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis[J]. Clin Gastroenterol H, 2021, 19(7): 1436-1442. doi: 10.1016/j.cgh.2020.08.007 pmid: 32777555
[55]	Semmler G, Pomej K, Bauer DJM, et al. Safety of direct oral anticoagulants in patients with advanced liver disease[J]. Liver int, 2021, 41(9): 2159-2170. doi: 10.1111/liv.14992 pmid: 34152697

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 55

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Su Rui, Wang Cunkai, Wang Dingxin, Cai Conghui, Zhang Jian, Hou Hongtao, Bai Yun. Efficacy and safety of anticoagulant therapy in patients with cirrhosis: A meta-analysis [J]. Clinical Focus, 2025, 40(4): 293-303.
[2]	Lin Tao, Du Taoming, Li Ya, Feng Yuling, Song Huizhen, Yu Qin. Value of T₂WI signal intensity and gadobemeglumine enhanced MRI hepatobiliary phase parameters in evaluating liver function of cirrhosis patients [J]. Clinical Focus, 2025, 40(3): 251-256.
[3]	Qian Chenying, Yan Wenjun, Huang Yan, Zhao Zhi. Analysis of risk factors for multidrug-resistant bacterial infection in patients with decompensated cirrhosis [J]. Clinical Focus, 2025, 40(2): 143-146.
[4]	Zhang Shasha, Zhao Yingchun, Zhou Hongxia. Effect of low-level viremia on the incidence of hepatocellular carcinomas in patients with hepatitis B cirrhosis treated with entecavir [J]. Clinical Focus, 2024, 39(11): 980-983.
[5]	Wang Qingli;Yang Lin;Liu Qi. Clinical observation on effect of coffeic acid on leukocyte anal platelet count in patients with cirrhosis [J]. Clinical Focus, 2015, 30(9): 1027-1.0281e+007.
[6]	Ge Xiuzhen;Wang Yuming;Zheng Zhongqing;Wang Tao;Wang Bangmao. Risk factors in poor prognosis after endoscopic variceal ligation and endoscopic injection sclerotherapy of esophageal varices caused by liver cirrhosis [J]. Clinical Focus, 2015, 30(3): 250-252256.
[7]	. [J]. CLINICAL FOCUS, 2014, 29(3): 350-350.
[8]	HE Qing-hong;HUANG Wei. Application of color Doppler sonography predicting cirrhotic portal hypertension with esophageal varices rupture hemorrhage [J]. CLINICAL FOCUS, 2014, 29(3): 295-297.
[9]	XIAO Qi;FENG Ai-dong;LIU Zhi-quan;FENG Jun-hua;DU Rui-qing;YE Li-hong;MEI Zhi-qin;DAI Er-hei. Value and impact factors of transient edoi:graphy in diagnosis of hepatitis B cirrhosis [J]. CLINICAL FOCUS, 2013, 28(8): 855-857860.
[10]	ZHAO Tian-yu;MA Chun-ye;LI Chun-yan. Analysis of cirrhosis patients with hepatic encephalopathy prognostic factors [J]. Clinical Focus, 2013, 28(4): 406-408.
[11]	WANG Jun-ming;CHEN Chun-yan;LI Yan;HANG Jing-xian;ZHANG Zhi-gang. Relationship between fatty liver and carotid atherosclerosis in different age populations [J]. Clinical Focus, 2013, 28(1): 11-13.
[12]	ZHANG Jing;SANG Hai-tong. Impact of hepatorenal function and clinical outcomes in patients with liver cirrhosis combined with systemic inflammatory response syndrome [J]. Clinical Focus, 2012, 27(24): 2117-2120.
[13]	. [J]. Clinical Focus, 2012, 27(22): 1979-1980.
[14]	LI Chun-sheng;GUO Jin-bo;XU Yun-feng;TIAN Hui;WEI Juan;ZHANG Guo-zun;LIU Lei;FANG Shu-ming;ZHANG Xiao-lan. Effects of salvia miltiorrhiza monomer IH764-3 on collagen metabolism and mechanism in hepatic stellate cells [J]. Clinical Focus, 2012, 27(17): 1502-1505.
[15]	. [J]. Clinical Focus, 2012, 27(6): 550-552.